Simcere Innovation, Inc.

On May 18, 2020, Simcere Pharmaceutical Group announced the collaboration with Primary Peptides, a privately held biotech company in Canada, on exclusive license to develop and commercialize an innovative product for the treatment ofstroke. https://lnkd.in/dKJsQxk

Simcere and Primary Peptides Launch Exclusive China Partnership On May 18, 2020, Simcere announced the collaboration with Primary Peptides, a privately held biotech company in Canada, on exclusive license to develop and commercialize an innovative product for the treatment of stroke.

Simcere Innovation takes the health of its employees and community seriously in the face of the COVID-19 pandemic. This is a difficult time for all of us and we have been seeking ways to help our community. As a biotechnology research company, we specialize in developing cell & gene therapies that fundamentally improve the lives of patients suffering from currently incurable diseases. We share the same goal as the frontline medical workers – treat all patients. During this pandemic, Simcere Innovation has a duty to support our colleagues in various medical institutions in the fight against COVID-19. Working together with Simcere Pharmaceutical Group, we have donated a supply of personal protective equipment to our colleagues at hospitals in America, including Dana-Farber Cancer Institute, Boston Children's Hospital, Brigham and Women's Hospital, URMC Strong Hospital, and others.

We have received thank you letters from these hospitals, and they appreciate Simcere Innovation’s sense of social responsibility and generosity. As always, Simcere Innovation will continue these efforts to protect our healthcare workers, slow the spread of the virus, and keep our community healthy. We are all in this together.